Status:
ENROLLING_BY_INVITATION
Lithium for Parkinson's: an Extension Trial
Lead Sponsor:
State University of New York at Buffalo
Conditions:
Parkinson Disease
Eligibility:
All Genders
45-80 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have complete...
Detailed Description
In observational studies, small daily doses of lithium from smoking cigarettes have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has bee...
Eligibility Criteria
Inclusion
- All PD patients completing STUDY00007253 or STUDY00008239 at the University at Buffalo will be eligible.
- No unstable cardiac, medical, neurologic or psychiatric condition in the opinion of the PI.
- No current use of illicit drugs or current alcohol abuse in the opinion of the PI.
- No history of brain surgery or possible need for brain surgery including deep brain stimulation (DBS) for at least 24 weeks in the opinion of the PI.
- Women with child bearing potential will need a negative pregnancy test and not be nursing an infant at screening. Women with child bearing potential will need to report using barrier method or hormonal contraception.
- Willing and able to sign informed consent and follow study procedures.
Exclusion
Key Trial Info
Start Date :
August 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06592014
Start Date
August 9 2024
End Date
November 1 2026
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UBMD Neurology
Williamsville, New York, United States, 14221